Industry
CSL’s hemophilia drug approved for sale in Europe
Jan. 10, 2017
South Korean biopharmaceuticals company SK Chemicals said Tuesday that a hemophilia treatment it licensed out to its partner CSL Ltd. has been approved for sale in Europe, marking another major market entry breakthrough.The European Medicines Agency, Europe’s drug regulator, granted marketing and sales approval for Afstyla, a biologic drug for hemophilia A, to CSL Behring, a subsidiary of CSL Ltd.Afstyla, or NBO601 (SK Chemicals)Afstyla was originated by SK Chemicals and licensed out to Australi